A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804 (Dacomitinib)
Phase of Trial: Phase I/II
Latest Information Update: 13 Jul 2015
Price : $35 *
At a glance
- Drugs Dacomitinib (Primary)
- Indications Orofacial cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms WOO
- 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Sep 2014 Status changed from not stated to active, no longer recruiting.
- 02 Aug 2014 New trial record